BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25046748)

  • 21. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
    Badgwell B; Blum M; Estrella J; Chiang YJ; Das P; Matamoros A; Fournier K; Mansfield P; Ajani J
    J Am Coll Surg; 2015 Jul; 221(1):83-90. PubMed ID: 26002780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
    Noh SH; Yoo CH; Chung HC; Roh JK; Shin DW; Min JS
    Oncology; 2001; 60(1):24-30. PubMed ID: 11150904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic variation rs10484761 on 6p21.1 derived from a genome-wide association study is associated with gastric cancer survival in a Chinese population.
    Kang M; Ding X; Xu M; Zhu H; Liu S; Wang M; Wu D; Tong N; Gong W; Zhou J; Zhang Z
    Gene; 2014 Feb; 536(1):59-64. PubMed ID: 24325909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin.
    Zhang XL; Shi HJ; Wang JP; Tang HS; Wu YB; Fang ZY; Cui SZ; Wang LT
    World J Gastroenterol; 2014 Aug; 20(32):11347-55. PubMed ID: 25170221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic value of the tumor deposit in N0 gastric cancer by propensity score matching analysis].
    Zhi C; Yang W; Li N; Zhang Z; Hua Y; Liu H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):172-179. PubMed ID: 30799540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
    Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2.
    Miyashiro I; Furukawa H; Sasako M; Yamamoto S; Nashimoto A; Nakajima T; Kinoshita T; Kobayashi O; Arai K;
    Gastric Cancer; 2011 Aug; 14(3):212-8. PubMed ID: 21336855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).
    Iwasaki Y; Sasako M; Yamamoto S; Nakamura K; Sano T; Katai H; Tsujinaka T; Nashimoto A; Fukushima N; Tsuburaya A;
    J Surg Oncol; 2013 Jun; 107(7):741-5. PubMed ID: 23400787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.
    Hwang JE; Hong JY; Kim JE; Shim HJ; Bae WK; Hwang EC; Jeong O; Park YK; Lee KH; Lee JH; Cho SH; Chung IJ
    Jpn J Clin Oncol; 2015 Jun; 45(6):541-6. PubMed ID: 25759484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.
    Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C
    Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study.
    Persiani R; Rausei S; Pozzo C; Biondi A; Barone C; Cananzi FC; Schinzari G; D'Ugo D
    Ann Surg Oncol; 2008 Aug; 15(8):2146-52. PubMed ID: 18543037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
    Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
    Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen.
    Shen J; Wei J; Wang H; Yang Y; Yue G; Wang L; Yu L; Xie L; Sun X; Bian X; Zou Z; Qian X; Guan W; Liu B
    PLoS One; 2013; 8(10):e75564. PubMed ID: 24124496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
    Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
    Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.
    Kubo T; Kawano Y; Himuro N; Sugita S; Sato Y; Ishikawa K; Takada K; Murase K; Miyanishi K; Sato T; Takimoto R; Kobune M; Nobuoka T; Hirata K; Takayama T; Mori M; Hasegawa T; Kato J
    Gastric Cancer; 2016 Jul; 19(3):827-38. PubMed ID: 26486506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
    Okabe H; Hata H; Ueda S; Zaima M; Tokuka A; Yoshimura T; Ota S; Kinjo Y; Yoshimura K; Sakai Y;
    J Surg Oncol; 2016 Jan; 113(1):36-41. PubMed ID: 26604064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of TS and ABCB1 gene polymorphisms on survival outcomes of 5‑FU-based chemotherapy in a Chinese population of advanced gastric cancer patients.
    Chen J; Ying X; Zhang L; Xiang X; Xiong J
    Wien Klin Wochenschr; 2017 Jun; 129(11-12):420-426. PubMed ID: 28074308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
    Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
    [No Abstract]   [Full Text] [Related]  

  • 39. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population.
    Du M; Wang W; Jin H; Wang Q; Ge Y; Lu J; Ma G; Chu H; Tong N; Zhu H; Wang M; Qiang F; Zhang Z
    Oncotarget; 2015 Oct; 6(31):31255-62. PubMed ID: 26384301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.